Does anyone know precisely how or wether issuance of a patent for a gene
sequence like BRCA1 (or p53, DCC etc. etc.) affects the ability of a hospital
clinical lab to obtain and use (and charge for) DNA sequence information for
Much thanks in advance for any help/opinions..